Abstract. Isoform-specific antibodies to TGF01, TGF02, and TGF03 proteins were generated and have been used to examine the expression of these factors in the developing mouse embryo from 12 .5-18 .5 d post coitum (d.p.c.). These studies demonstrate the initial characterization of both TGFs2 and /33 in mammalian embryogenesis and are compared with TGF01. Expression of one or all three TGFO proteins was observed in many tissues, e.g., cartilage, bone, teeth, muscle, heart, blood vessels, lung, kidney, gut, liver, eye, ear, skin, and nervous tissue. Furthermore, all three TGFO proteins demonstrated discrete cell-specific patterns of expression at various stages of development and the wide variety of tissues expressing TGF0 proteins represent all three primary embryonic germ lay-P OLYPEPTIDE growth factors such as the 0-type transforming growth factors (TGFos) mediate many cellcell interactions that occur during embryonic development (reviewed in Mercola and Stiles, 1988; Whitman and Melton, 1989; Nilsen-Hamilton, 1990 ). Complementary DNA clones havebeen isolated for five TGFS species (TGFos 1-5); however, purified or recombinant protein has been obtained only for TGF$s 1-3 (Derynck et al., 1985 (Derynck et al., , 1988 Madisen et al., 1988; ten Dijke et al., 1988; Jakowlew et al., 1988) . Moreover, only TGFos 1-3 have been found in mammals. The molecular structures of TGF01, (32, and 03 are very similar in that each polypeptide is synthesized as a prepro monomeric protein and is cleaved to yield a 112-amino acid polypeptide that remains associated withthe latent (pro) portion ofthe molecule (reviewed in Lyons and or Miller et al., 1990 . Biologically active TGF0 protein results from dimerization of the monomers (usually homodimers) and release of the latent peptide portion . Overall, the mature region of the TGF03 protein has -80% identity to the mature regions of both TGFO 1 and TGF02, however, the NH2-terminal or precursor regions of these three molecules Melissa Jones' present address is Department of Chemistry, Hendrix College, Conway, AR 72032 .
ers. For example, specific localization of TGFS1 was observed in the lens fibers of the eye (ectoderm), TGFS2 in the cortex of the adrenal gland (mesoderm), and TGF03 in the cochlear epithelium of the inner ear (endoderm). Compared to the expression of TGFO mRNA transcripts in a given embryonic tissue, TGFO proteins were frequently colocalized within the same cell type as the mRNA, but in some cases were observed to localize to different cells than the mRNA, thereby indicating that a complex pattern of transcription, translation, and secretion for TGFss 1-3 exists in the mouse embryo. This also indicates that TGF01, 02, and ,83 act through both paracrine and autocrine mechanisms during mammalian embryogenesis .
share only 27% sequence identity (ten Dijke et al., 1988; Derynck et al., 1988) . Some differences in the in vitro biological activities of TGF01 and TGF02 have been reported (Ohta et al., 1987; Jennings et al., 1988; Rosa et al., 1988; Merwin et al ., 1991) , however, in general, TGFos 1, 2, and 3 have qualitatively similar activities when added to cells in culture (Graycar et al., 1989) . In addition, competition studies with TGF,S1, TGF02, and TGFS3 suggest that these proteins interact with the same cell-surface binding molecules (Graycar et al., 1989) , although in some cell types, a given TGFO isoform may preferentially bind to an individual subset of these presumptive receptors (Segarini, 1990) .
In recent years, several converging lines of evidence have indicated that members of the TGFO family play important roles in many different embryonic processes (reviewed in Akhurst et al., 1991 or in Pelton and Moses, 1990a) . For example, in vitro TGFRs are mitogenic for cells derived from supporting tissues such as bone and cartilage but are inhibitory for many other cell types. The TGF0s also regulate differentiation (which may be stimulatory or inhibitory depending on the cell type), stimulate extracellular matrix deposition, are chemotactic for certain cells, and induce mesoderm formation during early embryogenesis . In an attempt to elucidate the in vivo activities ofthe TGFos, we and others have investigated the expression patterns of TGF# genes during embryonic development and a number of studies have now described the in vivo localization of mRNAs for TGFOs 1-3 during murine embryogenesis (Lehnert and Akhurst, 1988; Pelton et al., 1989 Pelton et al., , 1990a Akhurst et al ., 1990; Miller et al., 1990; Fitzpatrick et al., 1990; Millan et al., 1991; Schmid et al., 1991) . Recently we used in situ hybridization to directly compare the localization of TGFO1, /32, and /33 mRNA transcripts in the mouse embryo (Pelton et al., 1990a,b) . During mid to late embryogenesis, the murine TGFss 1-3 were shown to have overlapping but distinct patterns of mRNA expression . These patterns changed as development progressed and were often found in tissues undergoing morphogenetic alterations. For example, during the development of the whisker follicles of the mouse, the mRNA expression patterns for TGFOs 1-3 were all different in the immature follicle but were very Similar in the mature follicle . In situ hybridization studies with human embryonic tissue have produced results similar to those obtained with mouse embryos (Sandberg et al., 1988a,b ; Gatherer et al., 1990) .
Although in situ hybridization experiments designate which cells and tissues synthesize mRNA transcripts for a given gene, these studies cannot determine ifthe mRNAs are translated into proteins ; hence the relative amount of mRNA may not reflect similar amounts of protein. This phenomenon may have particular relevance in the study of TGFO expression. For example, Madisen et al. (1988) demonstrated that a human prostatic adenocarcinoma cell line produces higher levels of TGF01 and TGF02 mRNA but significantly higher levels of TGF02 than TGF01 protein. In addition, because the TGF,Bs 1-3 are secreted proteins, TGFO mRNAs may not colocalize with TGFO proteins . Indeed, by comparing their in situ hybridization studies with published immunohistochemistry data (Heine et al., 1987) , Akhurst and coworkers have already shown this to be true for TGF01 mRNA and protein (Lehnert and Akhurst, 1988; .
Using isoform-specific antibodies for TGFO1, 02, and (33, we have investigated the expression of TGFO proteins in the mouse embryo and compared the distribution of these proteins with their respective mRNAs. Our results show that TGFOs 1-3 are expressed in unique temporal and spatial patterns in a wide range of embryonic tissues, suggesting that these factors play multiple roles during morphogenesis and organogenesis. Moreover, when compared with the TGFO in situ hybridization studies, the data presented here indicate that all three mammalian forms of TGFO (, Q1, 02, and (33) act through both paracrine and autocrine mechanisms during murine embryonic development .
Materials and Methods

Mouse I7ssues
Staged embryos (Theiler, 1989) were obtained from matings of ICR outbred female (Harland Sprague Dawley) and Swiss-Webster male mice (Taconic Farms, Germantown, NY) . Noon on the day of vaginal plug was considered 0.5 days p.c . Pregnant females were killed via cervical dislocation and the 12 .5-18.5 d.p.c . embryos were placed immediately in ice-cold 4 % paraformaldehyde/PBS .
Antibody Preparation
Peptides of each TGF(3 isoform were synthesized using a 430A peptide synThe Journal of Cell Biology, Volume 115, 1991 thesizer (Applied Biosystems, Inc., Foster City, CA), incorporating the t-boc solid phase synthesis method followed by hydrofluoride cleavage. The following amino acid residues were used : TGF,61 and TGF02, residues 4-19 ; TGF03, residues 9-20. The peptides were purified by high pressure liquid chromatography using a gradient composed of 0.1% trifluoracetic acid and 100% acetonitrile. Each peptide (5.0 mg) was dissolved in 0.1 M NaHC03 and coupled to KLH at a 1 :1 ratio (wt/wt), by adding 3-ul vol of 1 .25 % glutaraldehyde 10 times over a period of 3 h . Rabbits were initially immunized with 500 ug of each peptide and subsequently boosted with 250 rug every 2 .5 wk. Antibody titer was determined by ELISA using the appropriate corresponding uncoupled peptide and alkaline phosphatase goat anti-rabbit IgG as the second antibody (Promega Biotec, Madison, WI) . The antisera did not cross-react with the TGFO peptides that were not used as immunogen . Each antiserum was purified by ammonium sulfate precipitation (31 .3%), followed by affinity chromatography using the respective immunogenic peptide. The peptide (8.0 mg) was coupled to 2 ml of TresylSepharose (Pharmacia Fine Chemicals, Piscataway, NJ) overnight according to the manufacturer's instructions . The purified IgG was eluted with 50 mM glycine (pH 2 .5) into Tris buffer (pH 7.2) for neutralization, dialyzed against TBS, aliquoted, and stored frozen . Each antipeptide antiserum was tested for both immunoreactivity with the corresponding mature isoform of the TGF(3 molecule and for cross-reactivity with each other TGFO isoform by Western blot analysis .
Western Blot Analysis
Recombinant human TGFS1 and TGF,83 were generously provided by Dr. Michael Palladino and Dr. Rik Derynck, respectively, of Genentech, Inc. (Palo Alto, CA) . Native porcine TGF02 was purchased from R & D Systems (Minneapolis, MN) . Human and porcine TGFO amino acid sequences are identical . Each TGFO molecule was reduced with a final concentration of 0.1 M DTT, subjected to SDS-PAGE using a gradient polyacrylamide gel of 10-20% and subsequently transferred to a nitrocellulose membrane for 1 h at 100 V using the Biorad Miniblot System (Bio-Rad Laboratories, Cambridge, MA) . The membranes were blocked with 3 % non-fat dry milk in TBS (0 .01 M Tris, 0.15 M NaCl, pH 8 .0) for 1 h and directly incubated overnight in purified anti-peptide IgG in TBS containing 0.1% 'Iween 20 (TBST) at the following dilutions : TGF#1, 1:50 ; TGF#2 and TGFS3, 1 :25 . The membranes were washed with TBST and incubated with alkaline phosphatase-labeled goat anti-rabbit IgG (Promega Biotec) at a dilution of 1 :3,000 for 1 h . The blot was developed with NBT/BCIP (Promega Biotec) .
Immunohistochemistry
The protocol used for these studies was a modified version of the method reported in Heine et al . (1987) . Tissues were fixed overnight in 4 % paraformaldehyde/PBS, dehydrated in increasing concentrations of ethanol, and embedded in paraffin wax (Fischer Scientific Co., Pittsburgh, PA) . Sections of 5-7 lum were cut and floated onto slides coated with 3-triethoxysilylpropylamide (Sigma Chemical Co .) . The sections were submerged in TBS/ 0 .1% (vol/vol) Triton X-100 at room temperature for 15 min followed by TBS for 5 min, methanol for 2 min, and methanol/0.6% (vol/vol) hydrogen peroxide for 30 min . Slides were subsequently washed at room temperature in methanol for 2 min, TBS for 5 min, and three times in TBS/0.1 % (wt/vol) BSA for 3 min . After treatment with hyaluronidase (1 mg/ml in 100 mM sodium acetate, 0.85 % (wt/vol) NaCl) and three washes in TBS/0 .1% BSA, excess protein was blocked with 5 % normal swine serum in TBS/0.5 % BSA for 15 min at room temperature. Tissue sections were incubated with primary antibodies at a concentration of 5 pg/ml (diluted in TBS containing 5 % swine serum and 0.1 % BSA) overnight at 4°C . Control slides were incubated with either an IgG fraction of normal rabbit serum at 5 ug/ml (diluted in TBS containing 5 % swine serum and 0.1 % BSA) or without primary antibodies . Tissues were then washed in TBS/0.1% BSA and incubated for 60 min at room temperature with biotinylated swine antirabbit secondary antibody in TBS/0.1% BSA . After washes in TBS/0.1% BSA, the sections were exposed to avidin-biotin complex for 60 min at room temperature and again washed in TBS/0.1 % BSA. Slides were reacted with 0.05 % (wt/vol) DAB in 50 mM Tris-HC1 (pH 7.4) with 0.1% (vol/vol) hydrogen peroxide for 5 min and counterstained in haematoxylin.
Results
Antibody Specificity
Western Blot Analysis . The specific immunoreactivity of ( Fig . 1, lane 2) , or rTGFs3 (Fig. 1, lane 3) . No crossreactivity was observed among any of the TGFIB isoforms. The specificity of the individual antisera was further demonstrated after complete absorption of the immunoreactivity with 10 M excess of the corresponding peptide (data not shown) . Lastly, the ability of the antipeptide antibodies to react (but not cross react) on a Western blot with the appropriate native TGFfll, TGFft2, and TGFS3 molecules purified from human umbilical cord tissue further suggests that these antibodies are specific for their respective proteins (L . I . Gold, manuscript in preparation) .
Immunohistochentistry. 'Ib ensure the specificity of the anti TGFS antisera for immunohistochemical studies, serial tissue sections were used for control and experimental slides . Control slides were reacted with either (a) the IgG fraction of normal rabbit serum (at the same concentration as the primary antibody) in place of the peptide antibodies ; or (b) no primary antibody. Fig . 2 shows examples of control sections directly compared against experimental sections . The epidermis and hair follicles in the skin of a 17.5 d.p.c . mouse showed strong immunoreactivity with TGFSI antibodies (Fig. 2 B) , while absolutely no staining was observed with normal rabbit IgGs (Fig . 2 A) . Similarly, while the keratinized epithelium of the palate and tongue of a 17.5 d.p.c embryo showed intense staining with TGFSI antibodies, no staining was observed using the normal rabbit IgGs (com- Millan et al. (1991) .
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Immunohistochemical Localization ofTGFO Proteins
The results of the immunohistochemical localization of TGFss 1-3 are summarized in 'Fable I . Data not shown in Figs. 2-11 are referred to in Table I .
The Embryonic Skeletal System . Chondrification centers for most bones are first seen in the embryo at -13-14 d.p.c. with centers of ossification usually appearing 2-3 d later (Rugh, 1990) . At 12 .5 d.p.c., chondrocytes in the ribs and vertebrae showed strong TGF03 staining but only very weak staining for TGFOI or TGF02 . The cartilage rudiments in other bones at 12 .5 d .p.c . showed little TGF03 staining. From 13.5 to 15.5 d.p.c ., TGF03 staining in the chondrocytes remained high and as the maturing chondrocytes became hypertrophic, TGFO1 (Fig . 3 , A and B) and TGF02 expression was seen . TGF01 levels were especially high in the perichondrium (Fig. 3, A and B) . By 16 .5 d.p.c., high levels of TGFOI were localized to the periosteum of several bones (Fig . 3 , C and D) as well as in the maturing chondrocytes of various cartilage rudiments . Although little TGF02 or TGF03 was detected in the periosteum, both were found in osteocytes of bone and maturing chondrocytes such as those of the tracheal cartilage . The TGF03 staining in bone was found in the cytoplasm of osteocytes, while the TGF02 staining was found predominantly in the extracellular matrix surrounding the osteocytes (Fig . 3 E) . TGF(31 immunoreactivity in the 17.5 d.p.c . embryo was found in the developing maxilla ( Fig. 3 F) , an intramembranous bone, as well as in the periosteum of endochondral bones (Fig . 3, C and D) . Whereas TGF,61 and TGF,62 were both still present at high levels in osteogenic bone and hypertrophic cartilage at this stage, TGF03 staining had diminished (Fig. 3 
, C-F) .
It has been previously demonstrated that at 16.5 d.p.c ., very high levels of TGFO mRNAs are found in the embryonic tooth, primarily in the odontoblast and mesenchymal pulp cells . However, TGFO proteins in the 17.5 d.p.c . tooth were localized to additional structures . For example, although TGFO1 mRNA was very abundant in the pulp cells, TGFSI antibody staining was seen at highest levels in the ameloblast layer (Fig . 3 G) . In addition, while TGF02 mRNA was found at high levels in the odontoblast layer and to a lesser extent in the pulp cells, TGF02 protein was observed at high levels in both the odontoblast and pulp cells (Fig. 3 H) . TGF03 immunostaining was found at low levels in both the pulp cells and the ameloblasts but was not seen in the odontoblast layer.
Tote Embryonic Circulatory System. Previous reports have shown that at 7 d.p.c., TGFO1 mRNA was observed in cardiac mesoderm cells ; however, TGFOI protein could not be detected . Transcripts for TGF03 are restricted to the atrioventricular cushions of the 11 .5 d.p.c . heart and are not found in the ventricles . Although immunostaining for TGF#3 protein, and to a lesser extent for TGF0l and TGF02, was also present in the embryonic heart from 12 .5 through 16 .5 d.p.c ., as seen in the tooth, there were differences in the TGFO mRNA and protein expression patterns in this tissue. For example, while TGF03 mRNA signal was high in the atrioventricular cushions and low in the ventricles of the 11 .5 d.p.c . mouse heart, TGF03 protein in the 12 .5 d.p.c. heart was high in the ventricles and atria and low in the atrioventricular cushions (Fig . 4, A and B) . By 17.5 d.p.c ., the staining for TGF01 and TGF(32 proteins was barely detectable above background while TGFQ3 staining remained strong. TGFO 1-3 staining was also found in blood vessels throughout the body. For example, TGF03 immunoreactivity was found in small vessels such as those entering the spinal cord (Fig. 4 D) as well as in large arteries and veins, such as the umbilical and pulmonary vessels (Fig . 4 C and 8, A and B) . The Embryonic Internal Organs . Thompson et al . (1989) have shown that TGF01 is localized to a subset of tubule cells in the cortex of the adult kidney and in the present study, TGFO proteins were also found in the embryonic kidney (Fig . 5, A-D) . In the 12 .5 d.p.c. embryo, the developing kidney consists of metanephric tubules lined by a cuboidal epithelium (Rugh, 1990) . At 12 .5 d.p.c ., TGF02 staining was present in a very restricted pattern in the basement membrane of the cuboidal epithelium . Neither TGFS1 nor TGF,53 was detected in the kidney at this stage . From 13.5 to 14 .5 d.p.c ., the TGF#2 expression in the basement membrane of the cuboidal epithelium increased in intensity and became more extensive (compare Fig . 5, A and B) . In contrast, dur-
The Journal of Cell Biology, Volume 115, 1991 ing this stage TGF#l and TGF03 were found in the cuboidal epithelial lining ofthe tubules, but not in the basement membranes . The expression of TGF01 and (33 remained high in the tubule epithelium throughout development . TGF02 staining was found in the basement membrane surrounding the tubules throughout development, but was also detectable in the tubule epithelium beginning at 15.5 d.p.c. (Fig. 5, C and D) in a pattern similar to TGFO1 and TGF03. Although the staining intensity for all three TGFos in the tubular epithelium of the kidney began to decrease at 17.5 d.p.c ., immunoreactivity for TGF01s 1-3 in the mesenchymal cells that support the tubules could be seen at this stage .
TGF01 has been previously localized to the zona fasiculata and zona reticularis in the cortex of the adult murine adrenal gland . Similarly, in our studies, the embryonic adrenal gland also shows very strong TGFO immunoreactivity. Adrenal blastemas are present in the 11 d.p.c. embryo, but these do not consolidate into cortex and medulla until 14 d.p.c . (Rugh, 1990) . Antibodies to TGFM and TGF02 showed only slight reactivity in the 13 .5 d.p.c. embryos ; however by 15.5 d.p.c., very strong staining for TGF02 (Fig . 5, C , E, and F) and TGFO1 was present in the cortex (presumptive zona fasiculata and zona reticularis) of the adrenal gland . This high level of expression for TGF01 and TGF02 persisted through 17.5 d.p.c . . Antibody staining was confined to the cortex since the medulla was negative for TGFO1 and /32 immunoreactivity (Fig. 5, E and F) . TGF03 did not appear to be present in the adrenal gland during these stages of development (13.5-17.5 d .p .c .) .
Using sequential elution of intestinal villus cells and Northern blot analysis, Barnard et al . (1989) have demonstrated that TGFO1 mRNA is present in a gradient along the villi epithelium in the adult rat intestine with highest levels evident at the tip of the intestinal villus. Immunohistochemistry reflects a similar gradient of TGFO proteins in the embryonic gut. Slight reactivity was seen at 14 . intestinal epithelium with all three TGFO antibodies, but by 15 .5 d.p .c. significantly stronger staining in these cells was observed (Fig . 6 A) . Similar to the TGF01 mRNA localization, staining appeared in a gradient fashion with the highest levels of TGFO proteins at the villus tip; lowest levels were in the intestinal crypts . Although TGFO1 staining remained high at 17.5 d.p.c . (Fig . 6 B) , TGF02 and TGF03 staining was not as intense as seen during earlier stages . In addition, the stratified squamous epithelium of the esophagus and forestomach in the 17.5 d.p .c. embryo showed intense TGFO1 staining (Fig . 6, C and D) , but immunoreactivity for TGF022 or 03 was not observed . Moderate staining for TGF01 (Fig .  6, A and C) , (32, and #3 was also seen in the smooth muscle of the esophagus and intestine .
Earlier studies have reported that TGF02 mRNA is localized to the submucosal layer of the embryonic gut (Pelton et al ., 1989) . TGF02 protein staining was also found in the basement membrane of this layer (Fig . 7, A and B) . At 13 .5 d.p.c., a well demarcated line of staining for TGF02 was evident just basal to the mucosal (epithelial) layer of the developing stomach and intestines (Fig. 7, A-C) . TGFS2 immunoreactivity was not seen in the muscosal layer of the stomach nor in the surrounding mesenchymal layers, although staining was observed in the epithelial cells of the intestine (Fig . 7 C) .
Previous reports have demonstrated the presence of TGF01 mRNA in megakaryocytes in the embryonic liver (Wilcox and Derynck, 1988; Lehnert and Akhurst, 1988) and although no TGFO mRNA has been found in liver hepatocytes, transcripts for TGF02 and 03 have been localized to the capsule surrounding the liver of the 11 .5 d .p.c . embryo . Similarly, light staining for TGF01 and (i3 was evident in megakaryocytes of the 12 .5 d.p.c. liver and TGF03 immunostaining was observed in the liver capsule at 13.5 d.p.c. (Fig . 7 D) . Although light staining for TGF03 was observed in the mesenchymal cells supporting the liver parenchyma (Fig . 7 D) , TGFO 1-3 staining of the hepatocytes was not detected . Heine et al. (1990) have used immunohistochemical analysis to demonstrate that TGFftI colocalizes in the embryonic lung with a number of important ECM proteins . In addition, earlier reports have shown that TGF0l, /32, and #3 mRNAs can be detected in the embryonic lung (Pelton et al., 1989 Lehnert and Akhurst, 1988; Millan et al., 1991 ; Schmid et al., 1991) . In the adult murine lung, the protein localization patterns in the proximal airways for all three TGFss are essentially identical (Pelton et al., 1991) . Correspondingly, TGF0 proteins in the embryonic mouse lung, showed strikingly similar patterns of expression (Fig . 8,  A-D) . Although slight TGFS 1-3 immunoreactivity was seen in the epithelium of 17.5 d.p.c . bronchioles, staining for the TGFss in the airways was seen primarily just basal to the respiratory epithelium (Fig . 8, A-D) . Moreover, staining for TGF,B 1-3 proteins was present in the smooth muscle cells in the walls of large blood vessels of the lung in a pattern similar to that seen in other large vessels of the embryo (compare Figs. 8, B and C and 4, C and D) . The highest levels of TGFS expression in the embryonic lung were seen in late gestation at 17.5-18.5 d.p.c . .
The Embryonic Sense Organs. The lens of the eye is derived from the surface embryonic ectoderm and by 12. of lens epithelium and lens fibers have formed by 13 d.p.c. (Rugh, 1990) . Intense staining for TGFOl was seen in the lens fibers as early as 14 .5 d.p.c . and remained strong through 17.5 d.p.c. (Fig . 9, A and B) . However, neither the lens epithelium nor the equatorial region of lens fiber elongation showed TGFS1 expression (Fig . 9, A and B) . TGF/62 and (33 staining was also observed in the lens fibers but was much weaker than that for TGFO1 . Previous studies have found the presence of TGF02 mRNA in the embryonic eye although not in the lens fibers (Millan et al ., 1991) . Moreover, recent reports have found TGFO protein activity (predominantly TGF02) in the aqueous and vitreous humors of adult eyes (Connor et al ., 1991 ; Jampel et al ., 1991) indicating that TGFO expression in the eye continues from the embryo into adulthood .
TGF02 mRNA is present in the ciliated cochlear epithelium of the inner ear Millan et al., 1991 ; Schmid et al ., 1991) . Immunostaining demonstrated that TGF02 protein was also found in the inner ear ; however, in contrast to theTGF02 mRNA, it was localized in the basement membrane just basal to the cochlear epithelium (Fig .  9 C) . This staining pattern was seen as early as 12 .5 d.p.c . and was consistently high through 17.5 d.p.c . . Although TGF/31 staining in the cochlea was not detected, TGF03 was localized throughout the cochlear epithelium in the 13 .5
The Journal of Cell Biology, Volume 115, 1991 d.p.c . embryo with the highest levels of immunoreactivity found in the apical region (Fig . 9 D) . Therefore, one of the most striking differences in immunostaining for TGFO isoforms was found in the ear. By 17.5 d .p.c ., TGF03 staining was no longer present in this epithelium .
The Embryonic Central Nervous System . The central nervous system (CNS) is unique in that it is one of the first embryonic systems to arise, yet one of the last to complete development (Rugh, 1990) . In general, the highest levels of TGFO immunoreactivity in the embryonic CNS were found with antibodies to TGFj32 and TGFa3 ; very little staining in the CNS was observed with TGFM antibodies . By 12 .5 d.p.c., the brain and spinal cord are well developed in the embryo and at this stage, TGF02 staining was already apparent in the meninges which envelop the CNS. The TGF02 staining in the meninges remained strong in the embryo from 13 .5 until 17.5 d.p.c . (Fig . 10, A-E) . This is in agreement with our in situ hybridization data which also shows TGF#2 mRNA expression in the meninges of the embryonic brain (Pelton et al ., 1989) . In the 17.5 d.p.c. embryo, TGF02 staining was also found in glia surrounding neurons in the brain and in spinal cord astrocytes (Fig. 10, F and G) . Although little TGFM immunoreactivity was seen in the CNS, TGF(33 staining was very strong in the brain, choroid plexus, and spinal cord (Fig . 10 H) . Both TGF#2 and 03 were localized to spinal cord astrocytes as early as 12 .5 d.p.c. (Fig. 10, G  and H) . Whereas, TGF,Q2 staining in the astrocytes was absent after 13 .5 d.p.c ., TGF#3 expression remained consistently high in these cells until late in gestation at 17.5-18.5 d.p.c .
The Embryonic Skin . The skin is formed first as a single cell layer, the periderm, and begins to differentiate into multiple layers at -14 d.p.c . (Rugh, 1990) . Significant staining for the TGFOs was first seen at this stage . At 14 .5 d.p.c., intense staining for TGFO1 and TGF03 was seen in the epithelial layer of the skin over the entire body, while only low levels of TGF02 could be detected at this stage (Fig. 11 A) . TGFfl1 and TGF03 were still localized to the epidermis and
The Joumal of Cell Biology, Volume 115, 1991 hair follicles through 17.5 d.p.c . (Fig. 2, A and B and 11, B and E) . In the 17.5 d.p.c. embryo, TGF01 was also expressed at very high levels in the keratinized squamous epithelium of the mouth (Fig . 2, C and D) . Earlier, we reported that TGF02 mRNA is localized to the dermis of 15 .5 d.p.c . mouse embryo skin and showed that by 18 .5 d.p.c ., the expression had switched from the dermis to the epidermis (Pelton et al ., 1989) . In contrast, TGF62 protein in the 15 .5 d.p.c . embryo was present in the dermis, epidermis and hair follicles of the skin (Fig . 11 C) . By 17.5 d.p.c ., most of the TGF02 staining in the dermis had faded but the staining in the epidermis remained strong (compare Fig . 11 C with D) . The highest levels of TGF02 immunostaining at this stage were seen in the epidermis of the skin, although the hair follicles were also positive for TGF02 staining.
Discussion
The data presented in these studies demonstrate that TGF01, TGF02, and TGF03 proteins are expressed during murine embryogenesis in a temporally and spatially regulated fashion. TGF,6 proteins are differentially expressed in the embryo and show isoform-specific and overlapping localization patterns. Moreover, in many tissues, the restriction of TGFfl proteins corresponds with morphogenetic events in the embryo. Comparison of TGFR protein and mRNA localizations is consistent with an intricate pattern of gene transcription, translation, secretion, storage, and degradation of TGF01, j32, and /33 during embryogenesis of the mouse . The disparate localization of TGFO mRNAs and proteins in some tissues and colocalization in others suggests that TGFf1-3 act through both paracrine and autocrine mechanisms in the morphogenesis of many organs .
In many tissues, TGFO proteins are found in the same cells as the TGF0 mRNA. For example, in situhybridization analysis demonstrates TGFfl 1-3 mRNA expression in the periosteum and osteocytes of developing skeletal tissue (Pelton et al ., 1990a) in a pattern very similar to the TGFO immunostaining presented here. All three TGFO mRNAs (Pelton et al., 1990a) and proteins colocalized in the osteocytes of the intramembranous bones of the head and TGF01 immunostaining in the perichondrium of developing cartilage was strikingly similar to the TGF,l31 mRNA pattern (Pelton et al., 1990a) in this tissue . TGF,62 and /33 also showed examples of colocalization of mRNA and protein including TGF02 in the submucosal layer of the gut, the pulp and odontoblasts of the tooth, the meninges of the CNS, and the skin; and TGF03 in the capsule of the liver, the choroid plexus, and the large blood vessels of the embryo. Thus, for the cells in these tissues, the TGF0s may be working in an autocrine fashion.
In contrast to this, in many instances, TGF0 mRNA and proteins were expressed in the same organ and yet were localized to different, but adjacent, cell types. For example, in the inner ear, transcripts for TGF02 are found in the cochlear epithelium (Pelton et al., 1990a; Schmid et al., 1991; Millan et al ., 1991) , while TGF,62 protein was restricted to the basement membranejust basal to the cochlear epithelium (Fig. 9 C) . Other examples of differential localization of TGF0 mRNAs and proteins were seen in the cartilage, brain, heart, teeth, and skin. It is well established that the TGFfs are secreted proteins, thus, certain cells may synthesize and release TGFO proteins into the extracellular matrix of adjacent cells which have the potential to respond to these factors. Thus, our TGFO immunolocalization data, in conjunction with previous TGF,Q in situ hybridization studies, suggest that in many tissues, the TGFas act in a paracrine mode. In support of this model, it has recently been shown that TGF#1 bound to type IV collagen remains biologically active (Vishwas et al ., 1990 ) and the ability of latent TGF01 to bind to heparin-Sepharose suggests thatit contains a specific heparin binding site (Wakefield et al., 1989) . Moreover, the latent forms of all TGF0s (except TGF02) contain the RGD integrin cellular recognition sequence (Ruoslahti and Pierschbacher, 1986 ). Thus, the extracellular matrix may act as a Pelton et al . TGFl3 Protein Expression during Mouse Development repository for TGF0 proteins. Indeed, at least one study has demonstrated that both freshly isolated and commercially available fibronectins can be contaminated with TGF/3 activity (Fava and McClure, 1987) .
Secretion and subsequent storage of TGF,Qs in the extracellular matrix may be a primary regulatory step in the production of mature, biologically active TGFO protein in vivo. Experiments by Sato et al. (1990) demonstrate that homotypic cultures of both endothelial cells and smooth muscle cells secrete TGF0 only in a latent form. However, if these two cell types are cocultured, a portion of the total TGFO secreted into the culture medium is activated . This suggests that in vivo, latent TGFOs may be produced and secreted by one cell type and activated in conjunction with an adjacent cell type. Activation of latent TGF,Q may be through serine proteases (e.g., plasmin ; Lyons et al., 1989) released locally by cells. This idea is supported by the observation that specific inhibitors ofplasmin block the activation of TGFfl in heterotypic cultures ofendothelial cells and pericytes (Sato and Rifkin, 1989) . Furthermore, Saksela and Rifkin (1990) have proposed a model whereby TGFO regulates the synthesis of plasminogen activator which in turn regulates the release of bFGF from extracellular matrix . Interestingly, a comparison of TGF02 and bFGF staining during embryogenesis demonstrates that both of these proteins are often found in the basement membrane next to an epithelial cell type (Figs. 5, A and B; 7, A-C; 8 C; 9 C; and Gonzalez et al., 1990) , indicating that these molecules may interact in vivo.
In some ofthe tissues we examined that express high levels of TGFO mRNA, very little TGFO protein was observed; the converse is also true. Other groups have also observed this phenomenon of TGF0 expression (Lehnert and Akhurst, 1988; Akhurst et al., 1991) . This may suggest that some of the reported mRNA or protein localization is nonspecific; however, the controls on our experiments have consistently shown thatthe TGFO probes used forthe in situ hybridization analysis as well as the TGF0 antibodies used in the immunohistochemistry are specific for their respective molecules. An alternative explanation that is consistent with this data is suggested by the work of Madisen et al. (1988) who found that although a prostatic adenocarcinoma cell line produced more TGFfl mRNA than TGFQ2, there was significantly more TGF02 protein than TGF01 present in these cells. Hence, it is possible that some cells transcribe but never translate a given TGFfl gene. It is known, for example, that TGF02 has at least five different transcripts in the mouse, but it is not known how many are translated into functional proteins (Miller et al., 1990) .
To date there have been no reports concerning the embryonic expression of TGF#2 and TGF03 proteins in mammals; however, several papers studying the distribution of TGF01 have been published (Heine et al., 1987 (Heine et al., , 1990 Thompson et al., 1989; Flanders et al., 1989) . Comparison of our results of TGF01 staining with these previous data shows that in some tissues the staining patterns were very similar, while in others they differ. For example, immunostaining for TGFOI has been reported in adult murine adrenocortical and kidney tubule cells as well as in murine embryonic chondrocytes and osteocytes (Heine et al., 1988) ; these tissues showed very strong staining for TGF01 in our study as well .
Similarly, Jakowlew et al . (1991) observed staining for TGF02, 03, and 04 (and to a lesser extent (31) in avian embryonic chondrocytes and cardiac myocytes in patterns much like those seen in the data presented here . Thus, in general, our results are consistent with the expression of TGFO1 as reported by others Heine et al ., 1988 ; Flanders, et al., 1988 ; Jakowlew et al ., 1991) , however, we do find some differences between our studies and those reported by Heine et al . (1988) . For example, the intense TGFOI staining in the epidermis of the embryonic skin (Figs . 2 B and 11, A-E) and in the epithelium of the gut (Figs . 6,  A-D) was not reported by Heine et al. (1988) . In contrast, Heine and colleagues found very strong TGFO1 staining in the atrioventricular valves of the heart which was not seen in our studies. There are several possible reasons for these discrepancies between our results and those of Heine et al. (1988) . The TGF01 antipeptide antibodies used in their experiments were raised against the first 30 amino acids in the mature region of TGF/31 (Heine et al., 1988) , while those used in our studies were raised against residues 4-19 of the TGFO1 amino acid sequence . Thus, while the antiTGFOl antibodies used in both studies react with (31, they may recognize different conformations of the protein . For example, Heine et al . (1988) found that embryos fixed in paraformaldehyde did not show immunoreactivity with their antibodies, while embryos fixed in Bouirfs fixative reacted strongly. In contrast, all embryos used for our immunohistochemistry were paraformaldehyde fixed . Alternatively, the possibility that some antibodies may cross-react with epitopes on other proteins should also be entertained ; however, Western blot analysis indicates that specific staining is achieved with each of the TGFO antibodies used in this study (Fig. 1) . Yang and Moses (1990) have demonstrated a range of in vivo cellular events (migration, proliferation, inhibition, angiogenesis, etc.) in the chick embryo chorioallantoic membrane in response to exogenously added TGFO1 . A large body of in vitro evidence also strongly suggests that many cellular activities critical to morphogenesis (cell proliferation, cell migration, cell differentiation, extracellular matrix production, etc.) are mediated by the TGF,Qs (reviewed in . The expression of TGF01, ,Q2, and ,Q3 during mouse embryogenesis, as presented in our results, correlates well with these in vivo and in vitro observations . For example, TGFO1 and (32 are found in the adrenal cortex of the mouse embryo (Fig . 5 , E and F) and human fetal adrenocortical cell differentiation is inhibited by TGF01 (Riopel et al ., 1989) . TGFO proteins also inhibit the growth of mesangial and proximal tubular cells in the kidney (Avner, 1990) , regulate differentiation, proliferation and extracellular matrix deposition in bone and cartilage cells (Centrella et al ., 1988) as well as in lung cells (Pelton and Moses, 1990b) , mediate transdifferentiation of cells in the embryonic heart (Potts and Runyan, 1989) , control the growth and differentiation of skin cells (Pittelkow et al ., 1988) , and appear to regulate morphogenesis, proliferation, and differentiation in astroglial cells of the central nervous system (Toru-Delbauffe et al ., 1990) . These are all cell types which we show to express TGFOs 1-3 during embryogenesis. A major challenge is to now provide evidence that the localization of TGF0l, /32, and 03 proteins in specific tissues and cells in the embryo has biological relevance for murine embryonic development . The most direct in vivo method to achieve this
The Journal of Cell Biology, Volume 115, 1991 end may be to construct transgenic and/or chimeric animals which either mis-express or do not express TGFO genes. Nonetheless, the temporal and spatial expression of TGFOs 1-3 at crucial steps in the morphogenesis of specific organs in the mouse undoubtedly implicates a role for these factors in the development of the mammalian embryo.
In conclusion, we have generated isoform-specific antibodies which recognize TGFSI, 02, or (33 and have used them to study the distribution of these three proteins during murine embryogenesis. We have observed that the expression patterns for each protein are both temporally and spatially unique . Similarly, these distinct but overlapping patterns of expression are seen for TGFOI, (32, and /33 mRNAs as well . While the mRNA and protein expression patterns do not always strictly coincide, TGFO protein is often found in cells or extracellular matrix positioned next to a cell type in which the mRNA is found in many tissues . This is consistent with the premise that during embryonic development, TGFO1, ,Q2, and (i3 may act through both autocrine and paracrine mechanisms . Currently, there is little evidence ascribing unique functions for these three closely related isoforms of TGFS. The expression patterns shown in this study of different isoforms of TGFO in dissimilar cell types, for example, in the eye and ear, may imply separate cell-specific functions for each of the TGFOs in vivo . Together with the known biological activities of the aTGFs, these data support the hypothesis that TGFM, /32, and (33 are important mediators of cell-cell interaction during embryonic development and may offer insight into an explanation for the evolutionary persistence of these very closely related proteins .
